Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

yourEra vs Hims & Hers

yourEra
Graded #23

Higher grade

vs+4
Hims & Hers
Graded #31

Lower grade

The verdict

yourEra takes it — 84/100 to 80/100.

yourEra grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A both-molecule compounded program that publishes its prices up front — semaglutide $199/mo, tirzepatide $299/mo — across a 50-state clinician network, with an optional coaching-plus-labs membership and a NAD+/microdosing menu on the side.

Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
82
82
Dose & formulationyourEra +4
82
78
Clinical oversightyourEra +3
85
82
Labs & monitoringyourEra +5
85
80
FulfillmentyourEra +2
86
84
Contract termsyourEra +5
85
80
yourEra · left barHims & Hers · right bar

The numbers

MetricyourEraHims & Hers
WeighScore84/10080/100
GradeBB−
Scorecard rank#23#31
Semaglutide$199/mo$199/mo
Tirzepatide$299/moNot disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
yourEra

Graded #23 · B

Strengths

  • Transparent, publicly listed pricing — many compounded competitors hide price behind a quiz
  • Both semaglutide and tirzepatide, not a single-drug menu, plus NAD+ and microdosing lines
  • Markets a 50-state licensed-clinician network; no insurance required, HSA/FSA accepted
  • Optional yourEra Optimum membership adds 1:1 coaching, a nutritionist, at-home lab draws and wearables

Where it loses points

  • Compounded semaglutide/tirzepatide are not FDA-approved (not the same as Wegovy/Ozempic/Zepbound)
  • Mid-market pricing ($199 sema / $299 tirz) — above the cheapest compounders
  • No brand-name lane and no oral route — weekly injectable only
  • Thin independent footprint; the 50-state and efficacy claims are self-reported
Hims & Hers

Graded #31 · B−

Strengths

  • Nationwide
  • Polished app
  • Strong brand trust

Where it loses points

  • Tirzepatide pricing inconsistently disclosed
  • Industry-wide compounding scrutiny

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 34 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard